we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
Company profile
Ticker
GERN
Exchange
Website
CEO
John Scarlett
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GERON CORPORATION
SEC CIK
Corporate docs
Subsidiaries
Geron UK Limited, incorporated • Geron Netherlands B.V., incorporated ...
IRS number
752287752
GERN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Mar 24
424B5
Prospectus supplement for primary offering
19 Mar 24
8-K
Other Events
19 Mar 24
8-K
Other Events
14 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Other Events
30 Jan 24
Transcripts
GERN
Earnings call transcript
2023 Q4
28 Feb 24
GERN
Earnings call transcript
2023 Q3
2 Nov 23
GERN
Earnings call transcript
2023 Q2
3 Aug 23
GERN
Earnings call transcript
2023 Q1
11 May 23
GERN
Earnings call transcript
2022 Q4
16 Mar 23
GERN
Earnings call transcript
2022 Q3
3 Nov 22
GERN
Earnings call transcript
2022 Q2
12 Aug 22
GERN
Earnings call transcript
2022 Q1
10 May 22
GERN
Earnings call transcript
2021 Q4
11 Mar 22
GERN
Earnings call transcript
2021 Q2
16 Aug 21
Latest ownership filings
4
Faye Feller
16 Feb 24
4
Anil Kapur
16 Feb 24
4
Scott Alan Samuels
16 Feb 24
4
MICHELLE ROBERTSON
16 Feb 24
4
ANDREW J GRETHLEIN
16 Feb 24
4
JOHN A SCARLETT
16 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.71 mm | 30.71 mm | 30.71 mm | 30.71 mm | 30.71 mm | 30.71 mm |
Cash burn (monthly) | 8.73 mm | 2.53 mm | 15.87 mm | 15.13 mm | 16.95 mm | 13.50 mm |
Cash used (since last report) | 52.27 mm | 15.16 mm | 95.00 mm | 90.59 mm | 101.44 mm | 80.80 mm |
Cash remaining | -21.56 mm | 15.55 mm | -64.29 mm | -59.88 mm | -70.73 mm | -50.09 mm |
Runway (months of cash) | -2.5 | 6.1 | -4.1 | -4.0 | -4.2 | -3.7 |
Institutional ownership, Q3 2023
76.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 203 |
Opened positions | 26 |
Closed positions | 25 |
Increased positions | 84 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 785.33 bn |
Total shares | 418.30 mm |
Total puts | 557.90 k |
Total calls | 712.00 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 46.20 mm | $97.95 bn |
BLK Blackrock | 37.16 mm | $78.78 bn |
Vivo Opportunity | 26.90 mm | $0.00 |
Vanguard | 26.65 mm | $56.50 bn |
Deep Track Capital | 25.70 mm | $54.48 bn |
STT State Street | 25.37 mm | $53.79 bn |
TCG Crossover Management | 23.38 mm | $49.56 bn |
NEA Management | 22.78 mm | $48.29 bn |
Growth Equity Opportunities 17 | 20.19 mm | $33.12 mm |
Vivo Capital | 16.52 mm | $35.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Feb 24 | Faye Feller | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 750,000 | 1.58 mm | 750,000 |
14 Feb 24 | Anil Kapur | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 750,000 | 1.58 mm | 750,000 |
14 Feb 24 | Scott Alan Samuels | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 850,000 | 1.79 mm | 850,000 |
14 Feb 24 | Michelle Robertson | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 850,000 | 1.79 mm | 850,000 |
14 Feb 24 | Andrew J Grethlein | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.1 | 1,200,000 | 2.52 mm | 1,200,000 |
News
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
18 Mar 24
Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?
15 Mar 24
Needham Maintains Buy on Geron, Raises Price Target to $5
15 Mar 24
What's Going On With Cancer Focused-Geron Stock On Friday?
15 Mar 24
Goldman Sachs Maintains Buy on Geron, Raises Price Target to $5
15 Mar 24
Press releases
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
14 Mar 24
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
5 Mar 24
Thinking about buying stock in Minim, GameSquare, Laser Photonics, Geron, or Mind Medicine?
1 Mar 24
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Feb 24